[go: up one dir, main page]

ES2172580T3 - 1,3-oxatiolanos sustituidos con propiedades antiviricas. - Google Patents

1,3-oxatiolanos sustituidos con propiedades antiviricas.

Info

Publication number
ES2172580T3
ES2172580T3 ES95915098T ES95915098T ES2172580T3 ES 2172580 T3 ES2172580 T3 ES 2172580T3 ES 95915098 T ES95915098 T ES 95915098T ES 95915098 T ES95915098 T ES 95915098T ES 2172580 T3 ES2172580 T3 ES 2172580T3
Authority
ES
Spain
Prior art keywords
substituted
oxatiolans
antivirical
properties
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95915098T
Other languages
English (en)
Inventor
Tarek S Mansour
Haolun Jin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
Shire BioChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire BioChem Inc filed Critical Shire BioChem Inc
Application granted granted Critical
Publication of ES2172580T3 publication Critical patent/ES2172580T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCION SE REFIERE A ENANTIOMEROS SIMPLES DE NUEVOS CISSUSTITUIDOS 1,3-OXATIOLANOS, DE FORMULA (I) EN DONDE R{SUB,1} ES HIDROGENO, Y R{SUB,2} ES CITOSINA O 5-FLUOROCITOSINA, Y ESTERES Y SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. ESTA INVENCION TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y AL USO DE ESTOS COMPUESTOS COMO AGENTES ANTIVIRALES, PARTICULARMENTE EN TERAPIA DE COMBINACION
ES95915098T 1994-04-20 1995-04-19 1,3-oxatiolanos sustituidos con propiedades antiviricas. Expired - Lifetime ES2172580T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/230,317 US5587480A (en) 1990-11-13 1994-04-20 Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties

Publications (1)

Publication Number Publication Date
ES2172580T3 true ES2172580T3 (es) 2002-10-01

Family

ID=22864746

Family Applications (3)

Application Number Title Priority Date Filing Date
ES04018075T Expired - Lifetime ES2286542T3 (es) 1994-04-20 1995-04-19 1,3-oxatiolanos sustituidos con propiedades antivirales.
ES01118810T Expired - Lifetime ES2228714T3 (es) 1994-04-20 1995-04-19 1,3-oxatiolanos sustituidos con propiedades antivirales.
ES95915098T Expired - Lifetime ES2172580T3 (es) 1994-04-20 1995-04-19 1,3-oxatiolanos sustituidos con propiedades antiviricas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES04018075T Expired - Lifetime ES2286542T3 (es) 1994-04-20 1995-04-19 1,3-oxatiolanos sustituidos con propiedades antivirales.
ES01118810T Expired - Lifetime ES2228714T3 (es) 1994-04-20 1995-04-19 1,3-oxatiolanos sustituidos con propiedades antivirales.

Country Status (12)

Country Link
US (1) US5587480A (es)
EP (3) EP1473294B1 (es)
JP (1) JPH09512526A (es)
AT (3) ATE360019T1 (es)
AU (1) AU693884B2 (es)
CA (1) CA2188283C (es)
DE (3) DE69525742T2 (es)
DK (3) DK0756595T3 (es)
ES (3) ES2286542T3 (es)
HK (1) HK1041487B (es)
PT (3) PT1153924E (es)
WO (1) WO1995029176A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US6228860B1 (en) * 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
ATE346651T1 (de) 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
TW536403B (en) 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
CN1141305C (zh) 1998-08-12 2004-03-10 三角药物公司 生产1,3-氧硫戊环核苷的方法
US6979561B1 (en) * 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
DE60134196D1 (de) 2000-02-10 2008-07-10 Mitsui Chemicals Inc Verfahren zur selektiven herstellung eines 1-phosphoryliertem zuckerderivativ-anomers und verfahren zur herstellung von nukleosiden
WO2002051852A1 (fr) * 2000-12-27 2002-07-04 Mitsui Chemicals, Inc. Procede de production d'un derive de saccharide non naturel
ES2293445T3 (es) * 2001-06-15 2008-03-16 Shire Biochem Inc. Procedimiento estereosselectivo para la preparacion de analogos de nucleosido.
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US7501514B1 (en) 2003-10-15 2009-03-10 Shire Biochem, Inc. Enantiomeric resolution of 2-substituted 4-substituted 1,3-oxathiolanes nucleosides
US7968703B2 (en) * 2005-03-07 2011-06-28 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
RU2430919C2 (ru) * 2005-03-14 2011-10-10 Шайр Канада Инк. Способы получения оптически активного цис-2-гидроксиметил-4-(цитозин-1'-ил)-1,3-оксатиолана или его фармацевтически приемлемых солей
AU2005329355B8 (en) * 2005-03-14 2012-02-23 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-Hydroxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2008118879A2 (en) * 2007-03-23 2008-10-02 Ardea Biosciences, Inc. Antiviral compositions comprising 2 compounds
EP2190839B1 (en) * 2007-09-28 2015-04-15 Avexa Limited A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes
DK2346890T3 (da) 2008-09-05 2013-06-24 Shire Canada Inc Separation af enantiomerer af 2,4-disubstituerede 1,3-oxathiolannucleosider
WO2010068756A2 (en) 2008-12-10 2010-06-17 Thesis Chemistry, Llc Process for manufacture of optically active 2-(acyloxymethyl)-1, 3 oxathiolanes
US8431699B2 (en) 2009-02-27 2013-04-30 Vertichem Corporation Method for manufacture of 2-oxoimidazolidines
TW201131192A (en) * 2010-03-01 2011-09-16 Univ Nat Central A co-crystal compound of optical devices
US20140315936A1 (en) * 2011-11-18 2014-10-23 Avexa Limited Apricitabine and pi combination therapy
JP2012136526A (ja) * 2012-02-09 2012-07-19 Shire Canada Inc 光学的に活性なｃｉｓ−２−ヒドロキシメチル−４−（シトシン−１’−イル）−１，３−オキサチオランまたはその薬学的に許容される塩の製造方法
WO2024016639A1 (zh) * 2022-07-21 2024-01-25 华创合成制药股份有限公司 一种抗病毒感染的化合物及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
DE3529263A1 (de) * 1985-08-16 1987-02-19 Hoechst Ag Verfahren zur herstellung von 2-oxo-1,3-dioxolanen
US5159067A (en) * 1987-01-28 1992-10-27 University Of Georgia Research Foundation Inc. 5'-Diphosphohexose nucleoside pharmaceutical compositions
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
DE3827134A1 (de) * 1988-08-10 1990-03-15 Bayer Ag Substituierte triazolyl- bzw. imidazolyl-hydroxyalkyldioxolane, verfahren zu ihrer herstellung und ihre verwendung als mikrobizide, oxiranyldioxolane, dioxolanylketone, oxiranylketone und (alpha)-halogenketone als zwischenprodukte und verfahren zu deren herstellung
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5118672A (en) * 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
AU8864191A (en) * 1990-11-13 1992-06-11 Biochem Pharma Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides

Also Published As

Publication number Publication date
DE69533458T2 (de) 2005-10-27
PT756595E (pt) 2002-08-30
PT1473294E (pt) 2007-06-11
DK1224940T3 (da) 2004-12-27
ATE275144T1 (de) 2004-09-15
WO1995029176A1 (en) 1995-11-02
DK1224940T4 (da) 2010-10-25
HK1041487B (en) 2005-01-07
HK1041487A1 (en) 2002-07-12
EP0756595A1 (en) 1997-02-05
EP1473294A3 (en) 2004-11-17
EP1153924A3 (en) 2001-11-21
HK1073460A1 (en) 2005-10-07
AU693884B2 (en) 1998-07-09
AU2211895A (en) 1995-11-16
PT1153924E (pt) 2005-01-31
DE69535476T2 (de) 2008-01-03
DE69525742T2 (de) 2002-09-26
DE69533458D1 (de) 2004-10-07
DE69525742D1 (de) 2002-04-11
ATE214066T1 (de) 2002-03-15
EP1473294B1 (en) 2007-04-18
ES2286542T3 (es) 2007-12-01
ATE360019T1 (de) 2007-05-15
HK1005544A1 (en) 1999-01-15
EP1153924B1 (en) 2004-09-01
DE69535476D1 (de) 2007-05-31
CA2188283A1 (en) 1995-11-02
DK1473294T3 (da) 2007-09-17
ES2228714T3 (es) 2005-04-16
JPH09512526A (ja) 1997-12-16
DK0756595T3 (da) 2002-06-17
CA2188283C (en) 2003-11-04
EP1153924A2 (en) 2001-11-14
EP0756595B1 (en) 2002-03-06
EP1473294A2 (en) 2004-11-03
US5587480A (en) 1996-12-24

Similar Documents

Publication Publication Date Title
ES2172580T3 (es) 1,3-oxatiolanos sustituidos con propiedades antiviricas.
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
SE9604786D0 (sv) New compounds
PH25571A (en) Alpha'-alkyl-4-amino-3-quinolinemethanols, 1-(4-aralkylamino-3-quinolinyl) alaknones, their use as medicaments
NO178189C (no) Tetrazolmellomprodukter
EP0324387A3 (en) Composition for treatment of ischemic disorder in organs
DE69216293D1 (de) 1,4-Disubstituierte Piperidinderivate, ihre Herstellung und therapeutische Verwendung
HU9501801D0 (en) Lactame-compounds as pharmaceutical active component
DE3362504D1 (en) 1-carboxyalkanoylindoline-2-carboxylic-acid esters, their preparation, pharmaceutical compositions containing them, and their therapeutic use
DE69118064D1 (de) Diamino-s-Triazinonderivate und diese enthaltende selbstlöschende polymere Zusammensetzungen
GB8829593D0 (en) Novel compounds
NZ229300A (en) Substituted-2-ethenyl-3,4,5,6-tetrahydrothieno (4,3,2-cf)(3)benzazepine derivatives and pharmaceutical compositions
ATE58135T1 (de) 1,3-oxathianderivate.
EP0802179A4 (en) DERIVATE SUBSTITUTED AMIDINONAPHTHYLESTER
FI873145A0 (fi) Nya tetracykliska indolderivat.
EP0760375A4 (en) Antitumor indolopyprolocarbazole derivative
FI905922A0 (fi) Antagonister foer a-adrenerga receptorer.
IT1262952B (it) Tetraalchilpiperidine, loro preparazione e loro impiego come stabilizzanti alla luce. (caso 153-5502)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 756595

Country of ref document: ES